Penpulimab
- Generic Name
- Penpulimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2350298-92-7
- Unique Ingredient Identifier
- IBS1BZ4E4I
- Indication
适用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤成人患者。
- Associated Conditions
- -
- Associated Therapies
- -
Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-04-26
- Target Recruit Count
- 23
- Registration Number
- NCT05347641
A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Akeso
- Target Recruit Count
- 60
- Registration Number
- NCT05244642
- Locations
- 🇨🇳
Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳Qilu Hospital of Shandong University, Jinan, Shandong, China
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
- Conditions
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 44
- Registration Number
- NCT05229003
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Sichuan Cancer Hospital and Research Institute
- Target Recruit Count
- 86
- Registration Number
- NCT05028504
- Locations
- 🇨🇳
Shaanxi Provincial Cancer Hospital, Xi'an, Shanxi, China
🇨🇳Sicchuan cancer hospital, Chengdu, Sichuan, China
🇨🇳The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, Hefei, China
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Akeso
- Target Recruit Count
- 278
- Registration Number
- NCT04974398
- Locations
- 🇦🇺
Genesis Care North Shore, St Leonards, New South Wales, Australia
🇺🇸Winship Cancer Institute/Emory University, Atlanta, Georgia, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT04970914
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳China-Japan friendship hospital, Beijing, Beijing, China
🇨🇳Hebei Petro China Central Hospital, Langfang, Hebei, China
Anlotinib or Penpulimab in Combination With RAI for DTC
- Conditions
- Interventions
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT04952493
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.